COVID-19

Monkeypox in a Young Infant — Florida, 2022 | Health Care Personnel Exposures to Subsequently Laboratory-Confirmed Monkeypox Patients — Colorado, 2022 | Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater — New York, June–August 2022 | Association of COVID-19 with New-Onset Alzheimer’s Disease | Impact of mandatory vaccination of healthcare personnel on rates of influenza and other viral respiratory pathogens | Monkeypox in Patient Immunized with ACAM2000 Smallpox Vaccine During 2022 Outbreak

Clinical and Genetic Risk Factors for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19 | Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors | Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study | Variant Influenza Virus Infections: Recommendations for Identification, Treatment, and Prevention for Summer and Fall 2022 | Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals

Clinical assessment of confirmed human monkeypox virus cases in Spain | Monkeypox Virus Infection across 16 Countries | Clinical characteristics of ambulatory and hospitalized patients with monkeypox | Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection | Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5–11 Years | Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age | Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine

Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater | Human-to-human transmission of monkeypox virus | What to Do If You Were Exposed to COVID-19 and its Isolation and Precautions for People with COVID-19 | Tecovirimat and the Treatment of Monkeypox — Past, Present, and Future Considerations | Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA | Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment

Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection — United States, August 2022 | Post–COVID-19 Symptoms and Conditions Among Children and Adolescents — United States, March 1, 2020–January 31, 2022 | Profiling post-COVID syndrome across different variants of SARS-CoV-2 | Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects | Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-Ritonavir

Symptoms and risk factors for long COVID in non-hospitalized adults | Post–COVID-19 Conditions Among Children 90 Days After SARS-CoV-2 Infection | Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022 | Pregnancy outcomes after SARS-CoV-2 infection by trimester: A large, population-based cohort study